North America Lymphangioleiomyomatosis Lam Market
시장 규모 (USD 10억)
연평균 성장률 :
% 
 예측 기간 |
2021 –2028 |
 시장 규모(기준 연도) |
USD 47.57 Million |
 시장 규모(예측 연도) |
USD 66.25 Million |
 연평균 성장률 |
% |
| 주요 시장 플레이어 |
>북미 림프관평활근종증(LAM) 시장, 질병 유형별(결절성 경화증 복합형, 산발성형), 유형별(진단, 치료), 합병증별(기흉, 유미흉, 신장 종양, 흉막 삼출액, 부기 및 체액 축적, 기타), 투여 경로별(경구, 비경구, 기타), 최종 사용자별(병원, 전문 진료소, 진단 센터, 재택 의료 및 기타), 유통 채널별(직접 입찰, 병원 약국, 소매 약국, 온라인 약국, 기타), 국가별(미국, 캐나다, 멕시코) 시장 동향 및 2028년까지의 예측.
시장 분석 및 통찰력: 북미 림프관평활근종증(LAM) 시장
북미 림프관평활근종증(LAM) 시장은 2021년부터 2028년까지의 예측 기간 동안 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 시장이 2021년부터 2028년까지의 예측 기간 동안 4.5%의 CAGR로 성장하고 있으며 2020년 4,757만 달러에서 2028년까지 6,625만 달러에 도달할 것으로 분석했습니다.
림프관평활근종증(LAM)은 폐계, 신장계, 림프계에 영향을 미치는 희귀한 낭포성 만성 폐 질환입니다. 림프계는 림프액과 면역 세포를 몸 전체로 운반하는 역할을 하는 조정된 혈관 네트워크로 구성되어 있습니다. LAM은 여성에게 발생합니다. 20~40세의 여성이 LAM 진단을 받습니다. 결절성 경화증이 있는 여성의 약 30%가 LAM에 걸리기 쉽습니다. 이는 종종 결절성 경화증 복합체(TSC), TSC 1 유전자의 돌연변이로 인해 발생합니다. 고립성 또는 산발성 LAM은 LAM이 단독으로 발생하는 것을 말합니다.
림프관세포성 근종증은 TSC 1과 TSC 2라는 두 유전자의 돌연변이 변화로 인해 발생합니다. 첫 번째 돌연변이 형태는 유전적이며 결절성 경화증 환자에게 발생합니다. 두 번째 형태는 결절성 경화증과 관련이 없으며 산발성 LAM이라고 합니다. 산발성 LAM이 있는 사람도 유전적 돌연변이가 있지만 유전자 돌연변이는 유전되지 않으며 자녀에게 유전되지 않습니다. 이러한 유전자 돌연변이가 발생하는 이유는 불분명합니다.
만성 낭포성 폐질환의 유병률 증가, 여성의 혈관근지방종과 결절성 경화증 증가, 임상 시험 증가. 림프관평활근종증(LAM) 시장 성장의 길을 닦습니다. 게다가 신흥 경제권에서 림프관평활근종증(LAM)의 성장 잠재력과 제품(진단 기계와 제네릭 의약품)의 증가는 림프관평활근종증(LAM) 시장 성장을 뒷받침합니다. 그러나 LAM 치료 비용의 증가, 부과된 엄격한 규제, 림프관평활근종증(LAM)이 개발도상국에서 접근이 불가능하다는 것은 시장 성장을 방해할 수 있는 제약입니다. 사용된 재료의 불일치는 시장 성장을 방해할 수 있는 제약입니다.
북미 림프관평활근종증(LAM) 시장 보고서는 시장 점유율, 신규 개발 및 제품 파이프라인 분석, 국내 및 현지 시장 참여자의 영향, 신규 수익 창출, 시장 규정 변경, 제품 승인, 전략적 의사 결정, 제품 출시, 지리적 확장 및 기술 혁신 측면에서 기회를 분석합니다. 림프관평활근종증(LAM) 시장 보고서는 시장 점유율, 신규 개발 및 국내 및 현지 시장 참여자의 영향, 신규 수익 창출, 시장 규정 변경, 제품 승인, 전략적 의사 결정, 제품 출시, 지리적 확장 및 기술 혁신 측면에서 기회를 분석합니다. 분석 및 시장 시나리오를 이해하려면 분석가 브리핑을 위해 당사에 문의하세요. 당사 팀은 원하는 목표를 달성하기 위한 수익 영향 솔루션을 만드는 데 도움을 드립니다.
북미 림프관평활근종증(LAM) 시장 범위 및 시장 규모
북미 림프관평활근종증(LAM) 시장은 제품, 방법, 상처 유형 및 최종 사용자를 기준으로 세분화됩니다. 세그먼트 간 성장을 통해 틈새 시장의 성장과 시장에 접근하는 전략을 분석하고 핵심 응용 분야와 타겟 시장의 차이점을 파악하는 데 도움이 됩니다.
- 질병 유형에 따라 글로벌 림프관평활근종증(LAM) 시장은 결절성 경화증 복합형 람(LAM)과 산발성 람(LAM)으로 세분화됩니다. 기계적 제품은 모노필라멘트 섬유 패드, 거즈, 파라핀 얇은 명주, 습식-건식 제거로 세분화됩니다. 2021년에는 결절성 경화증 복합형 람 세그먼트가 글로벌 림프관평활근종증(LAM) 시장을 지배하고 있는데, 결절성 경화증 환자에서 람의 유병률이 증가했기 때문입니다. 시장을 지배할 것으로 예측됩니다.
- On the basis of type, the global lymphangioleiomyomatosis (LAM ) market is segmented into diagnosis and treatment. The diagnosis segment is further segmented into blood test (vascular endothelial growth factor d (vegf-d)) and imaging test, lung function test, lung biopsy test, and others. The imaging test is further sub segmented into chest x-rays, chest CT scans, MRI of abdomen, and others. The lung biopsy test is further sub-segmented into transbronchial lung biopsy and video-assisted thorascopic lung biopsy. The treatment segment is further segmented into medication, oxygen therapy, and lung transplantation. The medication is further sub-segmented into mtor inhibitors and bronchodilators. The mtor inhibitors are further sub-segmented into sirolimus/ rapamycin, everolimus and others. The bronchodilators are further sub-segmented into albuterol, formoterol, salmeterol, and others. The lung transplantation is further sub-segmented into single-lung transplantation (SLT) and bilateral lung transplantation (BLT). In 2021 the treatment segment is dominating the global lymphangioleiomyomatosis (LAM) market owing to the rise in the number of cases and availability of generics, diagnostic and lung transplants.
- On the basis of complications, the global lymphangioleiomyomatosis (LAM) market is segmented into pneumothorax, chylothorax, kidney tumor, pleural effusions, swelling & fluid build-up, and others. In 2021, the pneumothorax segment is expected to dominate the global lymphangioleiomyomatosis (LAM) market due to the increased prevalence of female patients suffering from the chronic obstructive pulomonary disorder in the U.S., and timely diagnosis and treatment are predicted to dominate the market.
- On the basis of route of administration, the global lymphangioleiomyomatosis (LAM) market is segmented into oral, parenteral.The oral segment is further segmented into tablet, capsules, and others. The parenteral segment is further segmented into intravenous subcutaneous and others. In 2021, the oral segment is expected to dominate the global lymphangioleiomyomatosis (LAM) market due to the ease of absorption , and the medication being cost effective in the U.S. are predicted to dominate the market.
- On the basis of end users, the global lymphangioleiomyomatosis (LAM) market is segmented into hospitals, specialty clinics, diagnostic centers, home healthcare and others. In 2021, the hospitals segment is expected to dominate the global lymphangioleiomyomatosis (LAM) market due to the rise of diagnostics for lung disorders in the U.S., and the affordability of generic medications are predicted to dominate the market.
- On the basis of distribution channel, the global lymphangioleiomyomatosis (LAM) market is segmented into direct tender, hospital pharmacies, retail pharmacies, online pharmacies and others. In 2021, the direct tender segment is expected to dominate the global lymphangioleiomyomatosis (LAM) market due to the rise in access to sirolimus medications, the surge in the number of prescriptions daily, and the rise in the number of contacts for the supply of diagnostic medications and bronchodilators are predicted to dominate the market.
North America Lymphangioleiomyomatosis (LAM )Market Country Level Analysis
The North America lymphangioleiomyomatosis (LAM )market is analysed and market size information is provided by product, method, wound type, end user.
The countries covered in the North America lymphangioleiomyomatosis (LAM) market report are the U.S., Canada, and Mexico.
- In 2021, U.S. is dominating due to the presence of the largest consumer market with high GDP. Moreover, the U.S. has the highest household spending in the world and offers trade agreements with several countries making it the largest market for consumer products, including dandruff treatment products, due to the presence of major market players and increased technological advancement in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
The Growth Potential for Lymphangioleiomyomatosis (LAM )in Emerging Economies and the Strategic Initiatives by Market Players are creating new Opportunities in the North America Lymphangioleiomyomatosis (LAM )Market.
North America lymphangioleiomyomatosis (LAM) market also provides you with detailed market analysis for every country growth in particular industry with the lymphangioleiomyomatosis (LAM )sales, impact of advancement in the lymphangioleiomyomatosis (LAM ), and changes in regulatory scenarios with their support for the lymphangioleiomyomatosis (LAM )market. The data is available for historic period 2019 to 2020.
Competitive Landscape and North America Lymphangioleiomyomatosis (LAM )Market Share Analysis
북미 림프관평활근종증(LAM) 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 생산 현장 및 시설, 회사의 강점과 약점, 제품 출시, 제품 시험 파이프라인, 제품 승인, 특허, 제품 폭, 숨결, 응용 프로그램 우세, 기술 수명선 곡선이 포함된 세부 정보입니다. 위에 제공된 데이터 포인트는 림프관평활근종증(LAM) 시장과 관련된 회사의 초점에만 관련됩니다.
림프관평활근종증(LAM)을 제공하는 주요 회사로는 Pfizer Inc, Intas Pharmaceuticals Ltd, Apotex Inc, Amneal Pharmaceuticals LLC, Dr. Reddy's Laboratories Ltd, Novartis AG, Hikma Pharmaceuticals PLC, Teva Pharmaceutical USA Inc, Zydus Pharmaceuticals, Inc, TransMedics Group Inc, Terumo Corporation, Home Oxygen Company, Inogen, Paragonix Technologies, Inc, Care Dx, XVIVO, Taj Pharmaceuticals Limited, PulmOne Advanced Medical Devices, Morgan Scientific 등이 있습니다.
DBMR 분석가는 경쟁 우위를 이해하고 각 경쟁자에 대한 경쟁 분석을 별도로 제공합니다.
북미 림프관평활근종증(LAM)에 대한 시장 참여자들의 전략적 이니셔티브와 새로운 기술적 진보는 만성 폐질환 치료의 격차를 메우고 있습니다.
예를 들어,
- 2021년 2월, Apotex Inc(Apotex Pharmaceuticals Holdings, Inc의 자회사)의 장기 거부 약물은 주사기 배럴 측정 표시의 잘못된 라벨로 인해 Enoxaparin Sodium Injection, USP의 자발적인 전국적 리콜을 발표했습니다. Enoxaparin Sodium Injection은 폐색전증을 치료하는 데 사용됩니다. 이 리콜은 제네릭 의약품의 생산과 TSC-LAM 환자의 치료를 더욱 지연시킬 것입니다.
협력, 합작사업 및 기타 시장 참여자의 전략은 림프관평활근종증(LAM) 시장에서 회사 시장을 강화하고 있으며, 이는 기업이 북미 림프관평활근종증(LAM) 시장에 대한 제공 서비스를 개선하는 데에도 도움이 됩니다.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE NORTH AMERICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 NORTH AMERICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 DISEASE TYPE LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 MARKET INDICATION COVERAGE GRID
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 PIPELINE ANALYSIS
6 NORTH AMERICA LYMPHANGIOLEIOMYOMATOSIS MARKET: REGULATIONS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 RISE IN PREVALENCE OF CHRONIC CYSTIC LUNG DISORDERS
7.1.2 RISE OF ANGIOMYOLIPOMA AND TUBEROUS SCLEROSIS COMPLEX (TSC) IN WOMEN
7.1.3 RISE IN GOVERNMENT INITIATIVES AND ORGANIZATIONS
7.1.4 RISE IN CLINICAL TRIALS
7.1.5 HEALTHCAREREIMBURSEMENTFOR LYMPHANGIOLEIOMYOMATOSIS
7.2 RESTRAINTS
7.2.1 RISE IN COST FOR LYMPHANGIOLEIOMYOMATOSIS (LAM) TREATMENT
7.2.2 AVAILABILITY OF ALTERNATIVES
7.2.3 HIGH COMPLEXITY IN LAM
7.2.4 STRICT REGULATORY FRAMEWORK
7.3 OPPORTUNITIES
7.3.1 RISE IN HEALTHCARE EXPENDITURE
7.3.2 RISE IN PRODUCT APPROVALS
7.3.3 USE OF NON-INVASIVE PROCEDURE
7.4 CHALLENGES
7.4.1 SIDE EFFECTS FOUND DURING LAM TREATMENT
7.4.2 PATIENT COMPLIANCE DURING THE TREATMENT OF LAM
8 IMPACT OF COVID-19 ON NORTH AMERICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET
8.1 ANALYSIS ON IMPACT OF COVID-19 ON LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET
8.2 IMPACT ON PRICE OF LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET
8.3 IMPACT ON DEMAND OF LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET
8.4 IMPACT ON SUPPLY CHAIN OF LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET
8.5 STRATEGIC DECISIONS BY MANUFACTURERS OF LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET
8.6 CONCLUSION
9 NORTH AMERICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE
9.1 OVERVIEW
9.2 TUBEROUS SCLEROSIS COMPLEX LAM
9.3 SPORADIC LAM
10 NORTH AMERICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE
10.1 OVERVIEW
10.2 TREATMENT
10.2.1 MEDICATION
10.2.2 MTOR INHIBITORS
10.2.3 SIROLIMUS/ RAPAMYCIN
10.2.4 EVEROLIMUS
10.2.5 OTHERS
10.2.6 BRONCHODILATORS
10.2.7 ALBUTEROL
10.2.8 SALMETEROL
10.2.9 GLYCOPYRROLATE
10.2.10 OTHERS
10.2.11 OXYGEN THERAPY
10.2.12 LUNG TRANSPLANTATION
10.2.13 BILATERAL LUNG TRANSPLANTATION (BLT)
10.2.14 SINGLE-LUNG TRANSPLANTATION (SLT)
10.3 DIAGNOSIS
10.3.1 IMAGING TEST
10.3.2 CHEST X-RAYS
10.3.3 CHEST CT SCANS
10.3.4 MRI OF ABDOMEN
10.3.5 OTHERS
10.3.6 LUNG FUNCTION TEST
10.3.7 BLOOD TEST (VASCULAR ENDOTHELIAL GROWTH FACTOR D (VEGF-D))
10.3.8 LUNG BIOPSY
10.3.9 VIDEO-ASSISTED THORASCOPIC LUNG BIOPSY
10.3.10 TRANSBRONCHIAL LUNG BIOPSY
10.3.11 OTHERS
10.3.12 OTHERS
11 NORTH AMERICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS
11.1 OVERVIEW
11.2 PNEUMOTHORAX
11.3 PLEURAL EFFUSIONS
11.4 KIDNEY TUMOR
11.5 CHYLOTHORAX
11.6 SWELLING & FLUID BUILD-UP
11.7 OTHERS
12 NORTH AMERICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION
12.1 OVERVIEW
12.2 ORAL
12.2.1 TABLET
12.2.2 CAPSULES
12.2.3 OTHERS
12.3 PARENTERAL
12.3.1 INTRAVENOUS
12.3.2 SUBCUTANEOUS
12.3.3 OTHERS
13 NORTH AMERICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITALS
13.3 SPECIALTY CLINICS
13.4 DIAGNOSTIC CENTER
13.5 HOME HEALTHCARE
13.6 OTHERS
14 NORTH AMERICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 DIRECT TENDER
14.3 HOSPITAL PHARMACIES
14.4 RETAIL PHARMACIES
14.5 ONLINE PHARMACIES
14.6 OTHERS
15 NORTH AMERICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION
15.1 OVERVIEW
15.1 NORTH AMERICA
15.1.1 U.S.
15.1.2 CANADA
15.1.3 MEXICO
16 NORTH AMERICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
17 COMPANY PROFILE
17.1 TERUMO CORPORATION
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENTS
17.2 CAREDX, INC.
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENTS
17.3 PFIZER INC.
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENTS
17.4 NOVARTIS AG
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENTS
17.5 ZYDUS PHARMACEUTICALS, INC. (A SUBSIDIARY OF ZYDUS CADILA)
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 PRODUCT PORTFOLIO
17.5.4 RECENT DEVELOPMENTS
17.6 APOTEX INC
17.6.1 COMPANY SNAPSHOT
17.6.2 PRODUCT PORTFOLIO
17.6.3 RECENT DEVELOPMENTS
17.7 AMNEAL PHARMACEUTICALS LLC
17.7.1 COMPANY SNAPSHOT
17.7.2 REVENUE ANALYSIS
17.7.3 PRODUCT PORTFOLIO
17.7.4 RECENT DEVELOPMENTS
17.8 HIKMA PHARMACEUTICALS PLC
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 PRODUCT PORTFOLIO
17.8.4 RECENT DEVELOPMENTS
17.9 HERSILL
17.9.1 COMPANY SNAPSHOT
17.9.2 PRODUCT PORTFOLIO
17.9.3 RECENT DEVELOPMENTS
17.1 HOME OXYGEN COMPANY
17.10.1 COMPANY SNAPSHOT
17.10.2 PRODUCT PORTFOLIO
17.10.3 RECENT DEVELOPMENT
17.11 INTAS PHARMACEUTICALS, LTD
17.11.1 COMPANY SNAPSHOT
17.11.2 PRODUCT PORTFOLIO
17.11.3 RECENT DEVELOPMENT
17.12 INOGEN INC.
17.12.1 COMPANY SNAPSHOT
17.12.2 REVENUE ANALYSIS
17.12.3 PRODUCT PORTFOLIO
17.12.4 RECENT DEVELOPMENTS
17.13 MORGAN SCIENTIFIC
17.13.1 COMPANY SNAPSHOT
17.13.2 PRODUCT PORTFOLIO
17.13.3 RECENT DEVELOPMENTS
17.14 PULMONE ADVANCED MEDICAL DEVICES
17.14.1 COMPANY SNAPSHOT
17.14.2 PRODUCT PORTFOLIO
17.14.3 RECENT DEVELOPMENTS
17.15 PARAGONIX TECHNOLOGIES, INC
17.15.1 COMPANY SNAPSHOT
17.15.2 PRODUCT PORTFOLIO
17.15.3 RECENT DEVELOPMENTS
17.16 DR REDDY’S LABORATORIES LTD.
17.16.1 COMPANY SNAPSHOT
17.16.2 REVENUE ANALYSIS
17.16.3 PRODUCT PORTFOLIO
17.16.4 RECENT DEVELOPMENT
17.17 SANDOR
17.17.1 COMPANY SNAPSHOT
17.17.2 PRODUCT PORTFOLIO
17.17.3 RECENT DEVELOPMENT
17.18 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICALS INDUSTRIES LTD)
17.18.1 COMPANY SNAPSHOT
17.18.2 REVENUE ANALYSIS
17.18.3 PRODUCT PORTFOLIO
17.18.4 RECENT DEVELOPMENTS
17.19 TRANSMEDICS GROUP INC
17.19.1 COMPANY SNAPSHOT
17.19.2 REVENUE ANALYSIS
17.19.3 PRODUCT PORTFOLIO
17.19.4 RECENT DEVELOPMENTS
17.2 TAJ PHARMACEUTICALS LTD
17.20.1 COMPANY SNAPSHOT
17.20.2 PRODUCT PORTFOLIO
17.20.3 RECENT DEVELOPMENT
17.21 XVIVO
17.21.1 COMPANY SNAPSHOT
17.21.2 REVENUE ANALYSIS
17.21.3 PRODUCT PORTFOLIO
17.21.4 RECENT DEVELOPMENTS
18 QUESTIONNAIRE
19 RELATED REPORTS
표 목록
TABLE 1 NORTH AMERICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: PIPELINE ANALYSIS
TABLE 2 NORTH AMERICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 3 NORTH AMERICA TUBEROUS SCLEROSIS COMPLEX LAM IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 4 NORTH AMERICA SPORADIC LAM IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 5 NORTH AMERICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 6 NORTH AMERICA TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 NORTH AMERICA TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 8 NORTH AMERICA MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 9 NORTH AMERICA MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 10 NORTH AMERICA BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 11 NORTH AMERICA LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 12 NORTH AMERICA DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 13 NORTH AMERICA DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 14 NORTH AMERICA IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 15 NORTH AMERICA LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 16 NORTH AMERICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 17 NORTH AMERICA PNEUMOTHORAX IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 18 NORTH AMERICA PLEURAL EFFUSIONS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 19 NORTH AMERICA KIDNEY TUMOR IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 20 NORTH AMERICA CHYLOTHORAX IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 21 NORTH AMERICA SWELLING & FLUID BUILD-UP IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 22 NORTH AMERICA OTHERS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 NORTH AMERICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 24 NORTH AMERICA ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 NORTH AMERICA ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION , 2019-2028 (USD MILLION)
TABLE 26 NORTH AMERICA PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 NORTH AMERICA PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 28 NORTH AMERICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 29 NORTH AMERICA HOSPITALS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 30 NORTH AMERICA SPECIALTY CLINICS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 31 NORTH AMERICA DIAGNOSTIC CENTER IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 NORTH AMERICA HOME HEALTHCARE IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 33 NORTH AMERICA OTHERS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 34 NORTH AMERICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL 2019-2028 (USD MILLION)
TABLE 35 NORTH AMERICA DIRECT TENDER IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 36 NORTH AMERICA HOSPITAL PHARMACIES IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 37 NORTH AMERICA RETAIL PHARMACIES IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 38 NORTH AMERICA ONLINE PHARMACIES IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 39 NORTH AMERICA OTHERS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 40 NORTH AMERICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 1 NORTH AMERICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 2 NORTH AMERICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 3 NORTH AMERICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 4 NORTH AMERICA TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 5 NORTH AMERICA MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 6 NORTH AMERICA MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 7 NORTH AMERICA BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 8 NORTH AMERICA LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 9 NORTH AMERICA DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 10 NORTH AMERICA IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 11 NORTH AMERICA LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 12 NORTH AMERICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 13 NORTH AMERICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 14 NORTH AMERICA ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 15 NORTH AMERICA PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 16 NORTH AMERICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 17 NORTH AMERICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 18 U.S. LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 19 U.S. LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 20 U.S. TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 21 U.S. MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 22 U.S. MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 23 U.S. BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 24 U.S. LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 25 U.S. DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 26 U.S. IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 27 U.S. LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 28 U.S. LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 29 U.S. LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 30 U.S. ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 31 U.S. PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 32 U.S. LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 33 U.S. LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 34 CANADA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 35 CANADA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 36 CANADA TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 37 CANADA MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 38 CANADA MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 39 CANADA BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 40 CANADA LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 41 CANADA DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 42 CANADA IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 43 CANADA LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 44 CANADA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 45 CANADA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 46 CANADA ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 47 CANADA PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 48 CANADA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 49 CANADA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 50 MEXICO LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 51 MEXICO LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 52 MEXICO TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 53 MEXICO MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 54 MEXICO MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 55 MEXICO BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 56 MEXICO LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 57 MEXICO DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 58 MEXICO IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 59 MEXICO LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 60 MEXICO LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 61 MEXICO LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 62 MEXICO ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 63 MEXICO PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 64 MEXICO LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 65 MEXICO LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
그림 목록
FIGURE 1 NORTH AMERICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: NORTH AMERICA VS REGIONAL ANALYSIS
FIGURE 5 NORTH AMERICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 NORTH AMERICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: MARKET INDICATION COVERAGE GRID
FIGURE 10 NORTH AMERICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: SEGMENTATION
FIGURE 11 RISING PREVALENCE OF CHRONIC CYSTIC LUNG DISORDER , RISE IN CLINICAL TRIALS AND PRESENCE OF HEALTHCARE REIMBURSEMENT IS EXPECTED TO DRIVE THE NORTH AMERICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKETIN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 DISEASE TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET IN 2021 & 2028
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE NORTH AMERICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET AND IS ALSO EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF NORTH AMERICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET
FIGURE 15 PREVALENCE OF CHRONIC PULMONARY (LUNG) CYSTS, WHICH INCREASES WITH AGE
FIGURE 16 PREVALENCE OF CHRONIC OBSTRUCTIVE PULMONARY DISORDER , HIGHER IN FEMALES
FIGURE 17 NORTH AMERICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY DISEASE TYPE, 2020
FIGURE 18 NORTH AMERICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY TYPE, 2020
FIGURE 19 NORTH AMERICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY COMPLICATIONS, 2020
FIGURE 20 NORTH AMERICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY ROUTE OF ADMINISTRATION, 2020
FIGURE 21 NORTH AMERICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY END USER, 2020
FIGURE 22 NORTH AMERICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 23 NORTH AMERICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: SNAPSHOT (2020)
FIGURE 24 NORTH AMERICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY REGION (2020)
FIGURE 25 NORTH AMERICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY REGION (2021 & 2028)
FIGURE 26 NORTH AMERICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY REGION (2020 & 2028)
FIGURE 27 NORTH AMERICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY DISEASE TYPE (2021-2028)
FIGURE 28 NORTH AMERICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: SNAPSHOT (2020)
FIGURE 29 NORTH AMERICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY COUNTRY (2020)
FIGURE 30 NORTH AMERICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY COUNTRY (2021 & 2028)
FIGURE 31 NORTH AMERICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY COUNTRY (2020 & 2028)
FIGURE 32 NORTH AMERICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: BY DISEASE TYPE (2021-2028)
FIGURE 33 NORTH AMERICA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: COMPANY SHARE 2020 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.
